Gold Down, Investors Retreat After FDA Approves Potential COVID-19 Treatment
Investing.com
Published Aug 24, 2020 12:26AM ET
By Gina Lee
Investing.com – Gold was down on Monday morning in Asia, continuing a second consecutive week of losses.
Gold futures were down 0.36% at $1,940 by 12:25 AM ET (5:25 AM GMT). Stocks, which usually move inversely to gold, were up in Asia on Monday. Meanwhile, the dollar was flat on Monday.
The yellow metal was boosted on Friday by a stronger dollar alongside a slew of positive U.S. data. The data included the 5.86 million reading for July’s existing home sales, and both the manufacturing and service sectors purchasing managers' index (PMI), which remained above the 50-mark indicating expansion, beat forecasts prepared by Investing.com.
But investors retreated from the safe-haven asset after hopes were raised for a new COVID-19 treatment on Sunday. The U.S. Food and Drugs Administration (FDA) said that it had given “emergency use approval” for a new potential treatment that uses blood plasma from patients who have recovered from the virus to treat COVID-19.
Meanwhile, investors will be looking to U.S. Federal Reserve Chairman Jerome Powell’s speech at the Jackson Hole symposium, due to open on Thursday, for further clues on the U.S. monetary policy outlook. The Fed’s monetary policy framework review, focusing on a new inflation strategy, is widely expected to be covered in Powell’s speech after the release of the minutes form the Fed’s last meeting during the previous week disappointed investors.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.